Harold J. Burstein, MD, PhD | Authors

Articles

Genomic Assays for Chemotherapy Decisions in ER-Positive/HER2-Negative Breast Cancer

June 27, 2017

Harold J. Burstein, MD, PhD, institute physician, Dana-Farber Cancer Institute, associate professor of Medicine, Harvard Medical School, discusses a survey of how clinicians use genomic assays to assist in decision-making regarding the use of neoadjuvant and adjuvant chemotherapy for patients with ER-positive/HER2-negative early breast cancer.

Encouraging Findings With Ribociclib in HR+ Breast Cancer

December 21, 2016

Harold J. Burstein, MD, PhD, institute physician, associate professor of Medicine, Harvard Medical School, Dana-Farber Cancer Institute, discusses the CDK 4/6 inhibitor ribociclib and its clinical activity in patients with hormone receptor (HR)-positive breast cancer.